{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T11:58:11Z","timestamp":1765886291536,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.vaccine.2021.09.060","type":"journal-article","created":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T14:50:41Z","timestamp":1633099841000},"page":"6485-6491","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021"],"prefix":"10.1016","volume":"39","author":[{"given":"Van Nhi","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoang An","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thi Thanh An","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanh Tung","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phuong Thao","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thi Thu Hoai","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.09.060_b0005","unstructured":"World Health Organization. Coronavirus disease (COVID-19) 2021. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019 (accessed July 26, 2021)."},{"key":"10.1016\/j.vaccine.2021.09.060_b0010","unstructured":"World Health Organization. Status of COVID-19 Vaccines within WHO EUL\/PQ evaluation process 2021. https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/documents\/Status_COVID_VAX_15July2021.pdf (accessed July 26, 2021)."},{"key":"10.1016\/j.vaccine.2021.09.060_b0015","unstructured":"Our World in Data. Coronavirus (COVID-19) Vaccinations - Statistics and Research 2021. https:\/\/ourworldindata.org\/covid-vaccinations?country=VNM (accessed July 26, 2021)."},{"issue":"10269","key":"10.1016\/j.vaccine.2021.09.060_b0020","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet (London, England)"},{"issue":"7","key":"10.1016\/j.vaccine.2021.09.060_b0025","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study","volume":"21","author":"Menni","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.060_b0030","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4168\/aair.2021.13.4.526","article-title":"COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria\/Angioedema\/Anaphylaxis Working Group","volume":"13","author":"Kim","year":"2021","journal-title":"Allergy, Asthma Immunol Res"},{"key":"10.1016\/j.vaccine.2021.09.060_b0035","unstructured":"World Health Organization. MODULE 3: Adverse events following immunization MODULE 3 Adverse events following immunization n.d. https:\/\/www.who.int\/vaccine_safety\/initiative\/tech_support\/Part-3.pdf?ua=1 (accessed July 26, 2021)."},{"key":"10.1016\/j.vaccine.2021.09.060_b0040","unstructured":"European Medicines Agency. AstraZeneca\u2019s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets 2021. https:\/\/www.ema.europa.eu\/en\/news\/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood (accessed July 26, 2021)."},{"key":"10.1016\/j.vaccine.2021.09.060_b0045","unstructured":"Aleem A, Nadeem AJ. Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). StatPearls Publishing; 2021."},{"key":"10.1016\/j.vaccine.2021.09.060_b0050","unstructured":"Body Mass Index (BMI) - Healthy Weight, Nutrition, and Physical Activity. Centre for Disease Control and Prevention 2021. https:\/\/www.cdc.gov\/healthyweight\/assessing\/bmi\/index.html (accessed July 26, 2021)."},{"key":"10.1016\/j.vaccine.2021.09.060_b0055","unstructured":"National Institute of Nutrition. [Survey on Overweight - obesity and some related factors in Vietnamese people aged 25-64 years] 2019. http:\/\/viendinhduong.vn\/vi\/dinh-duong-nguoi-lon\/ket-qua-dieu-tra-thua-can---beo-phi-va-mot-so-yeu-to-lien-quan-o-nguoi-viet-nam-25--64-tuoi.html (accessed July 26, 2021). Vietnamese."},{"key":"10.1016\/j.vaccine.2021.09.060_b0060","unstructured":"GOV.UK. Coronavirus vaccine - weekly summary of Yellow Card reporting 2021. https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-vaccine-adverse-reactions\/coronavirus-vaccine-summary-of-yellow-card-reporting (accessed July 26, 2021)."},{"key":"10.1016\/j.vaccine.2021.09.060_b0065","unstructured":"Therapeutic Goods Administration (TGA). COVID-19 vaccine weekly safety report - 22-07-2021 2021. https:\/\/www.tga.gov.au\/periodic\/covid-19-vaccine-weekly-safety-report-22-07-2021 (accessed July 26, 2021)."},{"key":"10.1016\/j.vaccine.2021.09.060_b0070","unstructured":"Government of Canada. COVID-19 vaccine safety: Weekly report on side effects following immunization 2021. https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-safety\/ (accessed July 26, 2021)."},{"key":"10.1016\/j.vaccine.2021.09.060_b0075","doi-asserted-by":"crossref","unstructured":"CONSOLIDATED REGIONAL AND GLOBAL INFORMATION ON ADVERSE EVENTS FOLLOWING IMMUNIZATION (AEFI) AGAINST COVID-19 AND OTHER UPDATES Thirteenth report. Pan American Organization 2021.","DOI":"10.15408\/avicenna.v2i1.19832"},{"issue":"4","key":"10.1016\/j.vaccine.2021.09.060_b0080","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4168\/aair.2021.13.4.526","article-title":"COVID-19 Vaccine-associated Anaphylaxis and Allergic Reactions: Consensus Statements of the KAAACI Urticaria\/Angioedema\/Anaphylaxis Working Group","volume":"13","author":"Kim","year":"202113526","journal-title":"Allergy, Asthma Immunol Res"},{"issue":"10267","key":"10.1016\/j.vaccine.2021.09.060_b0085","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet (London, England)"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21012639?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21012639?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:02:54Z","timestamp":1759402974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21012639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":17,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0264410X21012639"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.060","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors influencing adverse events following immunization with AZD1222 in Vietnamese adults during first half of 2021","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.09.060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}